PAVmed Inc.

PAVM

US70387R4039

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
2.12 ^USD	-5.78%		+2.42%	-48.54%

May. 07	Pavmed Inc. Appoints Dennis Matheis to Board of Directors	CI
Mar. 27	Transcript : PAVmed Inc., Q4 2023 Earnings Call, Mar 27, 2024

PAVmed Inc. Provides Revenue Guidance for the Year 2021

February 22, 2021 at 08:30 am EST

PAVmed Inc. provided revenue guidance for the year 2021. For the year, the company GAAP revenue will be realized only on actual collections received or tests submitted for reimbursement.

Latest news about PAVmed Inc.

Pavmed Inc. Appoints Dennis Matheis to Board of Directors	May. 07	CI
Transcript : PAVmed Inc., Q4 2023 Earnings Call, Mar 27, 2024	Mar. 27
PAVmed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
PAVmed Inc. Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX	Mar. 21	CI
Lucid Diagnostics Inc. and Pavmed Inc. Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies	Dec. 12	CI
Transcript : PAVmed Inc., Q3 2023 Earnings Call, Nov 15, 2023	Nov. 15
PAVmed Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Pavmed Inc. Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Pre Cancer Detection	23-09-07	CI
Transcript : PAVmed Inc., Q2 2023 Earnings Call, Aug 16, 2023	23-08-16
North American Morning Briefing : Stock Futures -2-	23-08-16	DJ
PAVmed Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
PAVmed Secures Extension to Regain Compliance With Nasdaq Listing Rules	23-06-29	MT
PAVmed Inc.(NasdaqCM:PAVM) dropped from Russell Microcap Growth Index	23-06-23	CI
PAVmed Inc.(NasdaqCM:PAVM) dropped from Russell Microcap Index	23-06-23	CI
PAVmed Inc.(NasdaqCM:PAVM) dropped from Russell 3000E Growth Index	23-06-23	CI
PAVmed Inc.(NasdaqCM:PAVM) dropped from Russell 3000E Index	23-06-23	CI
Transcript : PAVmed Inc. - Shareholder/Analyst Call	23-06-21
Transcript : PAVmed Inc., Q1 2023 Earnings Call, May 17, 2023	23-05-17
North American Morning Briefing : Debt-Ceiling -2-	23-05-17	DJ
PAVmed Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Transcript : PAVmed Inc. - Shareholder/Analyst Call	23-03-31
Transcript : PAVmed Inc., Q4 2022 Earnings Call, Mar 15, 2023	23-03-15
PAVmed Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
PAVmed Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
PAVmed Inc. announced that it expects to receive $11.11111 million in funding from Lucid Diagnostics Inc. and others	23-03-12	CI

PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-12 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for PAVmed Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.12 USD

Average target price

15.38 USD

Spread / Average Target

+625.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
PAVMED INC.	-48.54%	20M
THERMO FISHER SCIENTIFIC	+11.73%	226B
DANAHER CORPORATION	+9.53%	188B
INTUITIVE SURGICAL, INC.	+14.63%	137B
BOSTON SCIENTIFIC CORPORATION	+27.47%	108B
SIEMENS HEALTHINEERS AG	-0.04%	63.19B
EDWARDS LIFESCIENCES CORPORATION	+13.73%	52.26B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.86%	51B
AGILENT TECHNOLOGIES, INC.	+7.72%	43.89B
GE HEALTHCARE TECHNOLOGIES INC.	+7.86%	38.07B

Other Advanced Medical Equipment & Technology

PAVmed Inc.

Equities

PAVM

US70387R4039

Advanced Medical Equipment & Technology

PAVmed Inc. Provides Revenue Guidance for the Year 2021

Latest news about PAVmed Inc.

Chart PAVmed Inc.

Company Profile

Income Statement Evolution

Ratings for PAVmed Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Advanced Medical Equipment & Technology